


PRODUCT INFORMATION



NSC 228155

Item No. 28856

CAS Registry No.: 113104-25-9
Formal Name: 4-nitro-7-[(1-oxido-2-pyridinyl)thio]-2,1,3-benzoxadiazole
MF: C₁₁H₆N₄O₄S
FW: 290.3
Purity: ≥98%
UV/Vis.: λ_{max}: 240, 267, 393 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NSC 228155 is supplied as a crystalline solid. A stock solution may be made by dissolving the NSC 228155 in the solvent of choice, which should be purged with an inert gas. NSC 228155 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of NSC 228155 in these solvents is approximately 10 mg/ml.

NSC 228155 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NSC 228155 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. NSC 228155 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

NSC 228155 is an activator of the EGF receptor (EGFR) and an inhibitor of the interaction between the kinase inducible domain (KID) of CREB and the KID-interacting (KIX) domain of CREB-binding protein (CBP; IC₅₀ = 0.36 μM).^{1,2} It increases phosphorylation of EGFR at Tyr1068 in MDA-MB-468 cells (EC₅₀ = 52 μM), as well as phosphorylation of ERK1 and ERK2.¹ NSC 228155 (100 μM) also induces transactivation of InsR, EphA1, ErbB2, ErbB3, IGF-1R, Mer, and ROR1 in MDA-MB-468 cells. It inhibits CREB-mediated transcription (IC₅₀ = 2.09 μM), as well as transcription mediated by the constitutively active mutant VP16-CREB (IC₅₀ = 6.14 μM), in HEK293T cell-based reporter assays.² NSC 228155 also inhibits *P. aeruginosa* ribonucleotide reductase (IC₅₀ = 26 μM) and is active against *P. aeruginosa* with an MIC value of 50 μM.³

References

1. Sakanyan, V., Angelini, M., Le Béhec, M., *et al.* Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. *Sci. Rep.* **4:3977**, (2014).
2. Xie, F., Li, B.X., Broussard, C., *et al.* Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription. *Bioorg. Med. Chem. Lett.* **23(19)**, 5371-5375 (2013).
3. Tholander, F., and Sjöberg, B.-M. Discovery of antimicrobial ribonucleotide reductase inhibitors by screening in microwell format. *Proc. Nat. Acad. Sci. USA* **109(25)**, 9798-9803 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM